ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Ginsenoside Rb1 protects hair cell-like HEI-OC1 cells against apoptosis by inhibiting the activation of the Fas system induced by the RhoA/ROCK/LIMK1 pathway.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSensorineural hearing loss (SNHL) is a prevalent clinical disorder in otorhinolaryngology, with cochlear ischemia/reperfusion (I/R) injury-induced hair cell apoptosis being a core pathogenic mechanism. Ginsenoside Rb1 (Rb1), a major active component of Panax ginseng, exhibits potent anti-apoptotic and neuroprotective effects, but its role and underlying mechanism in cochlear I/R injury remain elusive.
methodsThe hair cell-like HEI-OC1 cell line was employed to establish an in vitro cochlear I/R injury model via oxygen-glucose deprivation/reperfusion (OGD/R). Cell viability was evaluated using the CCK-8 assay to screen for the non-cytotoxic concentration of Rb1. LIMK1 knockdown was achieved by transfection with si-LIMK1, and the knockdown efficiency was verified by RT-qPCR and Western blot. Flow cytometry with Annexin V-FITC/PI staining was used to detect cell apoptosis. Western blot was performed to measure the protein expression levels of key molecules in the RhoA/ROCK/LIMK1 pathway and Fas system. The Rho/ROCK pathway inhibitor Y-27,632, the RhoA activator LPA, and Fas agonist antibody Jo2 were used to validate the regulatory relationships among the pathways.
resultsOGD/R significantly induced HEI-OC1 cell apoptosis, accompanied by activation of the RhoA/ROCK/LIMK1 pathway and Fas system. Rb1 pretreatment attenuated the OGD/R-induced reduction in cell viability and increase in apoptosis, while inhibiting the activation of the RhoA/ROCK/LIMK1 pathway and Fas system. LIMK1 knockdown attenuated OGD/R-induced Fas system activation and cell apoptosis. Notably, LPA attenuated the protective effects of Rb1 and restored RhoA/ROCK/LIMK1-related protein expression, whereas Jo2 attenuated Rb1-mediated protection without affecting the upstream pathway.
conclusionsGinsenoside Rb1 protects HEI-OC1 cells against OGD/R-induced apoptosis, and this protective effect is associated with reduced activation of the RhoA/ROCK/LIMK1 pathway and Fas system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.